Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?
Authors:
- 13 March 2012
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 21 (5) , 524-534
Abstract
Purpose: Infliximab, a chimeric monoclonal anti‐TNFα antibody, has been found to increase the risk of serious infections compared with the TNF receptor fusion protein etanercept in some studies. It is unclear whether the risk varies by patient characteristics. We conducted a study to address this question.Methods: We identified members of Kaiser Permanente Northern California who initiated infliximab (n = 793) or etanercept (n = 2692) in 1997–2007. Using a Cox model, we estimated the propensity‐score‐adjusted hazard ratio (HR) and 95% confidence interval (CI) of serious infections requiring hospitalization or opportunistic infections comparing infliximab initiators to etanercept initiators. We tested whether the adjusted HR differed by age, sex, race/ethnicity, body mass index, and smoking status.Results: The crude incidence rate of serious infections per 100 person‐years was 5.4 (95%CI: 3.8, 7.5) in patients <65 years and 16.0 (95%CI: 10.4, 23.4) in patients ≥65 years during the first 3 months following treatment initiation. Compared with etanercept, the adjusted HR during this period was elevated for infliximab in patients <65 years (HR: 3.01; 95%CI: 1.49, 6.07), but not in those ≥65 years (HR 0.94; 95%CI: 0.41, 2.13). Findings did not suggest that the HR varied by the other patient characteristics examined.Conclusions: An increased risk of serious infections associated with infliximab relative to etanercept did not appear to be modified by patients' sex, race/ethnicity, body mass index, or smoking status. There was an indication that the increased risk might be limited to patients <65 years. Additional studies are warranted to verify or refute this finding. Copyright © 2012 John Wiley & Sons, Ltd.Keywords
This publication has 41 references indexed in Scilit:
- Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune DiseasesJAMA, 2011
- Study design for a comprehensive assessment of biologic safety using multiple healthcare data systemsPharmacoepidemiology and Drug Safety, 2011
- The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsAnnals of the Rheumatic Diseases, 2011
- Impact of the medicare modernization act of 2003 on utilization and spending for medicare part B–covered biologics in rheumatoid arthritisArthritis Care & Research, 2010
- Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patientsJournal of Clinical Epidemiology, 2009
- Drug‐specific and time‐dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonistsArthritis & Rheumatism, 2007
- Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studiesArthritis & Rheumatism, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983